


RESEARCH REPORT



Immuno-Oncology Diagnostics

Market Forecasts for Immuno-Oncology Diagnostics by Assay Type,
Technology, Client and Country.
With Executive/Consultant Guides.
2023 to 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	21
1.1	Situation Analysis	22
1.2	Guide for Executives and Marketing Staff	24
1.3	Guide for Investment Analysts and Management Consultants	25
2	Introduction and Market Definition	26
2.1	What are Immuno-Oncology Diagnostics?	27
2.2	Immuno-oncology – the looming cure	29
2.2.1	Immuno-oncology Diagnostics Takes a Leading Role.....	31
2.3	Market Definition	32
2.3.1	Market Size	32
2.3.2	Currency	32
2.3.3	Years	32
2.4	Methodology	33
2.4.1	Methodology	33
2.4.2	Sources	33
2.4.3	Authors.....	33
2.5	Perspective: Healthcare and the IVD Industry	35
2.5.1	Global Healthcare Spending	35
2.5.2	Spending on Diagnostics	36
2.5.3	Important Role of Insurance for Diagnostics.....	38
3	Immunotherapy – Guide to Immune Technologies	39
3.1	The Immune System	40

3.1.1	Innate immune system	41
3.1.1.1	Surface barriers	42
3.1.1.2	Inflammation	43
3.1.1.3	Complement system	43
3.1.1.4	Cellular barriers	44
3.1.1.5	Natural killer cells	45
3.1.2	Adaptive immune system	46
3.1.2.1	Lymphocytes.....	46
3.1.2.2	Killer T cells	47
3.1.2.3	Helper T cells	49
3.1.2.4	Gamma delta T cells	50
3.1.2.5	B lymphocytes and antibodies	50
3.1.3	Tumor immunology – the immune surveillance system	52
3.2	Immuno Oncology Diagnostics	54
3.2.1	Checkpoint Assays	54
3.2.1.1	Outlook for Checkpoint Assays	58
3.2.2	Cytokine Assays	59
3.2.2.1	Outlook for Cytokine Assays	60
3.2.3	Genomic Germline.....	60
3.2.3.1	Outlook for Genomic Germline	61
3.2.4	Genomic Tumour	61
3.2.4.1	Outlook for Genomic Tumour.....	64
3.2.5	Tumor Microenvironment	65
3.2.5.1	Outlook for Tumor Microenvironment	66
3.2.6	Others.....	66

3.2.6.1	Outlook for Other Diagnostics.....	66
4	Industry Overview.....	67
4.1	Players in a Dynamic Market.....	68
4.1.1	Academic Research Lab.....	69
4.1.2	Diagnostic Test Developer.....	69
4.1.3	Instrumentation Supplier.....	70
4.1.4	Chemical/Reagent Supplier.....	70
4.1.5	Pathology Supplier.....	70
4.1.6	Independent Clinical Laboratory.....	71
4.1.7	Public National/regional Laboratory.....	71
4.1.8	Hospital Laboratory.....	72
4.1.9	Physicians Office Lab (POLs).....	72
4.1.10	Audit Body.....	73
4.1.11	Certification Body.....	73
5	Market Trends.....	75
5.1	Factors Driving Growth.....	76
5.1.1	Outcome potential.....	76
5.1.2	Companion Diagnostics.....	77
5.1.3	Funding.....	77
5.1.4	Technology Environment.....	77
5.1.5	Target Solutions.....	78
5.2	Factors Limiting Growth.....	79
5.2.1	Complex Role of Diagnostics.....	79
5.2.2	Clinical Trials Role.....	80
5.2.3	Protocols.....	80

5.3	Diagnostic Technology Development	81
5.3.1	Combinations - Issues and Complexity	81
5.3.2	Shifting Role of Diagnostics.....	83
5.3.3	Multiplexing and Foundation One.....	84
5.3.4	The Disruption Dynamic	85
5.3.5	The Race for Biomarkers	85
5.3.6	The Next Five Years.....	86
6	Cancer Immuno-Oncology Diagnostics Recent Developments	87
6.1	Recent Developments – Importance and How to Use This Section	88
6.1.1	Importance of These Developments.....	88
6.1.2	How to Use This Section.....	88
6.2	Integrated DNA Technologies Buys NGS Research Assays.....	88
6.3	Navignostics Using Single-Cell Spatial Proteomics.....	89
6.4	New Reference Samples for NGS-Based Cancer Tests	92
6.5	Spatial Proteomics Panel for Immuno-Oncology.....	93
6.6	dMMR, MSI Assays for Immunotherapy Patient Selection.....	94
6.7	OncoHost Expands Prophet Platform Research	100
6.8	Protein-Based Liquid Biopsy Panel Assesses TME.....	100
6.9	Oncimmune Announces Sixfold Revenue Increase	104
6.10	Mayo Clinic, Personalis Ink Collaboration.....	105
6.11	Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes	106
6.12	Qiagen, OncXerna Close Companion Dx Development Deal.....	109
6.13	Natera Test to Guide Therapy for Bladder Cancer	110
6.14	Veracyte Halio Acquisition to Boost Immuno-oncology Activity	113
6.15	Freenome Eyes New Dx Possibilities.....	115

6.16	Oncocyte Data has Potential as Immunotherapy Response Predictor	118
6.17	OncoDNA use HaliDx to Expand into North America	122
6.18	Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay .	123
6.19	Qiagen Expands Immuno-Oncology Portfolio	124
6.20	Immune Profiling System Redirected to Fight COVID-19	125
6.21	IncellDx Awarded PD-L1 Detection Patent	127
6.22	FDA Approves CDx for Trastuzumab	128
6.23	Promega Nabs CE Mark for Microsatellite Instability IVD	129
6.24	ArcherDx partners with AstraZeneca for Immuno-Oncology	130
6.25	Germline Results Guides Precision Therapy	131
6.26	Agilent PD-L1 Assay Gets FDA Approval.....	135
6.27	Bayer, OrigiMed Form Companion Diagnostic Development Alliance	136
6.28	Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy	136
6.29	SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures	137
6.30	Biocare Medical Launches 7 Novel IVD Antibodies	138
7	Profiles of Key Immuno-oncology Companies	141
7.1	10x Genomics, Inc.....	142
7.2	Abbott Laboratories.....	143
7.3	AccuraGen Inc.....	144
7.4	Aethlon Medical.....	146
7.5	Agilent/Dako	147
7.6	Anchor Dx	149
7.7	ANGLE plc	150
7.8	AVIVA Systems Biology	152

7.9	Baylor Miraca Genetics Laboratories.....	153
7.10	Becton, Dickinson and Company	155
7.11	Berkley Lights.....	157
7.12	BGI Genomics Co. Ltd	158
7.13	Bioarray Genetics.....	160
7.14	Biocartis	161
7.15	Biocept, Inc.....	162
7.16	Biodesix Inc.	163
7.17	BioFluidica	164
7.18	BioGenex.....	165
7.19	BioIVT	166
7.20	Biolidics Ltd.....	167
7.21	bioMérieux Diagnostics.....	168
7.22	Bioneer Corporation	170
7.23	Bio-Rad Laboratories, Inc.	171
7.24	Bio-Reference Laboratories.....	173
7.25	Bio-Techne	174
7.26	Bioview	175
7.27	Bolidics.....	176
7.28	Boreal Genomics.....	177
7.29	Bristol-Myers Squibb	178
7.30	Burning Rock	179
7.31	Cardiff Oncology	180
7.32	Caris Molecular Diagnostics.....	181
7.33	Castle Biosciences, Inc.	182

7.34	CellCarta.....	183
7.35	CellMax Life	184
7.36	Cepheid (Danaher)	185
7.37	Charles River Laboratories.....	187
7.38	Circulogene	188
7.39	Cizzle Biotech.....	189
7.40	Clinical Genomics	190
7.41	Cytolumina Technologies Corp.	191
7.42	Datar Cancer Genetics Limited	192
7.43	Diagnologix LLC.....	193
7.44	Diasorin S.p.A.	194
7.45	Dxcover	196
7.46	Element Biosciences	197
7.47	Enzo Biochem	198
7.48	Epic Sciences.....	199
7.49	Epigenomics AG.....	200
7.50	Eurofins Scientific	201
7.51	Fabric Genomics.....	203
7.52	Fluxion Biosciences.....	204
7.53	Freenome.....	205
7.54	FUJIFILM Wako Diagnostics.....	206
7.55	Fyr Diagnostics	207
7.56	GeneFirst Ltd.	208
7.57	Genetron Holdings	209
7.58	GenomOncology.....	210

7.59	GILUPI Nanomedizin.....	211
7.60	Guardant Health	212
7.61	HansaBiomed	213
7.62	HeiScreen	214
7.63	Helomics.....	215
7.64	HTG Molecular Diagnostics	216
7.65	iCellate	217
7.66	ICON PLC	218
7.67	Illumina	219
7.68	Incell Dx.....	220
7.69	Inivata.....	221
7.70	INOVIQ	222
7.71	Integrated Diagnostics	223
7.72	Invitae Corporation.....	224
7.73	Invivogen	225
7.74	Invivoscribe	226
7.75	Janssen Diagnostics	227
7.76	Lunglife AI Inc	228
7.77	MDNA Life SCIENCES, Inc.	229
7.78	MDx Health	230
7.79	Menarini Silicon Biosystems.....	231
7.80	Mesa Laboratories, Inc.	232
7.81	Millipore Sigma	233
7.82	Miltenyi Biotec	234
7.83	miR Scientific.....	235

7.84	Myriad Genetics/Myriad RBM	236
7.85	NantHealth, Inc.	237
7.86	Natera	238
7.87	NeoGenomics	239
7.88	NGeneBio.....	240
7.89	Novogene Bioinformatics Technology Co., Ltd.	242
7.90	Oncocyte.....	244
7.91	OncoDNA.....	245
7.92	Ortho Clinical Diagnostics	246
7.93	Oxford Nanopore Technologies	247
7.94	PamGene.....	248
7.95	Panagene	249
7.96	Perkin Elmer.....	250
7.97	Personal Genome Diagnostics	251
7.98	Personalis.....	252
7.99	Precipio	253
7.100	Precision Medicine Group	254
7.101	PrecisionMed.....	255
7.102	Predicine.....	256
7.103	Promega.....	257
7.104	Qiagen.....	259
7.105	Rarecells SAS	261
7.106	RareCyte	262
7.107	Roche Molecular Diagnostics	263
7.108	ScreenCell.....	265

7.109	Sense Biodetection.....	266
7.110	Siemens Healthineers	267
7.111	simfo GmbH.....	268
7.112	Singlera Genomics Inc.	269
7.113	Singular Genomics.....	270
7.114	Singulomics.....	271
7.115	SkylineDx	272
7.116	Standard BioTools	273
7.117	Stilla Technologies.....	274
7.118	Sysmex Inostics	275
7.119	Tempus Labs, Inc.	276
7.120	Thermo Fisher Scientific Inc.	277
7.121	Todos Medical.....	279
7.122	Ultima Genomics	280
7.123	Veracyte.....	281
7.124	Volition	282
7.125	Vortex Biosciences.....	283
8	The Global Market for Immuno-Oncology Diagnostics	284
8.1	Global Market Overview by Country	285
8.1.1	Table – Global Market by Country.....	285
8.1.2	Chart - Global Market by Country.....	286
8.2	Global Market by Assay Type - Overview.....	287
8.2.1	Table – Global Market by Assay Type	287
8.2.2	Chart – Global Market by Assay Type – Base/Final Year Comparison.....	288
8.2.3	Chart – Global Market by Assay Type – Base Year	289

8.2.4	Chart – Global Market by Assay Type – End Year.....	290
8.2.5	Chart – Global Market by Assay Type – Share by Year	291
8.2.6	Chart – Global Market by Assay Type – Segments Growth.....	292
8.3	Global Market by Technology - Overview	293
8.3.1	Table – Global Market by Technology	293
8.3.2	Chart – Global Market by Technology – Base/Final Year Comparison	294
8.3.3	Chart – Global Market by Technology – Base Year	295
8.3.4	Chart – Global Market by Technology – End Year.....	296
8.3.5	Chart – Global Market by Technology – Share by Year	297
8.3.6	Chart – Global Market by Technology – Segments Growth	298
8.4	Global Market by Customer - Overview.....	299
8.4.1	Table – Global Market by Customer.....	299
8.4.2	Chart – Global Market by Customer – Base/Final Year Comparison	300
8.4.3	Chart – Global Market by Customer – Base Year	301
8.4.4	Chart – Global Market by Customer – End Year	302
8.4.5	Chart – Global Market by Customer – Share by Year	303
8.4.6	Chart – Global Market by Customer – Segments Growth.....	304
9	Global Immuno-Oncology Diagnostic Markets – By Application.....	305
9.1	Checkpoint.....	306
9.1.1	Table Checkpoint – by Country	306
9.1.2	Chart - Checkpoint Growth.....	307
9.2	Cytokine	308
9.2.1	Table Cytokine – by Country	308
9.2.2	Chart - Cytokine Growth.....	309
9.3	Germline Genetic	310

9.3.1	Table Germline Genetic – by Country.....	310
9.3.2	Chart - Germline Genetic Growth.....	311
9.4	Genetic Tumor.....	312
9.4.1	Table Genetic Tumor – by Country.....	312
9.4.2	Chart - Genetic Tumor Growth.....	313
9.5	Tumor Microenvironment.....	314
9.5.1	Table Tumor Microenvironment – by Country.....	314
9.5.2	Chart – Tumor Microenvironment Growth.....	315
9.6	Other.....	316
9.6.1	Table Other – by Country.....	316
9.6.2	Chart - Other Growth.....	317
10	Global Immuno-Oncology Diagnostic Markets – By Technology.....	318
10.1	NGS.....	319
10.1.1	Table NGS – by Country.....	319
10.1.2	Chart - NGS Growth.....	320
10.2	PCR.....	321
10.2.1	Table PCR – by Country.....	321
10.2.2	Chart - PCR Growth.....	322
10.3	Fish/IHC.....	323
10.3.1	Table Fish/IHC – by Country.....	323
10.3.2	Chart - Fish/IHC Growth.....	324
10.4	Chem/IA.....	325
10.4.1	Table Chem/IA – by Country.....	325
10.4.2	Chart - Chem/IA Growth.....	326
10.5	Other Technology.....	327

- 10.5.1 Table Other Technology – by Country327
- 10.5.2 Chart – Other Technology Growth.....328
- 11 Global Immuno-Oncology Diagnostic Markets – By Customer329
 - 11.1 Pharma.....330
 - 11.1.1 Table Pharma – by Country330
 - 11.1.2 Chart - Pharma Growth.....331
 - 11.2 Clinic.....332
 - 11.2.1 Table Clinic – by Country332
 - 11.2.2 Chart - Clinic Growth.....333
 - 11.3 Other Customer Genetic.....334
 - 11.3.1 Table Other Customer – by Country334
 - 11.3.2 Chart - Other Customer Growth.....335
- 12 Appendices.....336
 - 12.1 Growth of Approved IVD Test Menu337
 - 12.2 Prevalence of Cancer Treatments338
 - 12.3 United States Medicare System: Clinical Laboratory Fees Schedule339
 - 12.4 The Most Used IVD Assays.....431
 - 12.5 The Highest Grossing Assays436

Table of Tables

- Table 1 List of Cancers by Mortality30
- Table 2 Overview of Innate and Adaptive Immunity41
- Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment55
- Table 4 FDA Approved Companion diagnostics in Cancer treatment.....62

Table 5 Market Players by Type.....	69
Table 6 Five Factors Driving Growth	76
Table 7 Three Factors Limiting Growth.....	79
Table 8 - Global Market by Region.....	285
Table 9 Global Market by Assay Type	287
Table 10 Global Market by Technology	293
Table 11 Global Market by Customer	299
Table 12 Checkpoint by Country	306
Table 13 Cytokine by Country	308
Table 14 Germline Genetic by Country	310
Table 15 Genetic Tumor by Country.....	312
Table 16 Tumor Microenvironment by Country	314
Table 17 Other by Country	316
Table 18 NGS by Country.....	319
Table 19 PCR by Country	321
Table 20 Fish/IHC by Country	323
Table 21 Chem/IA by Country	325
Table 22 Other Technology by Country	327
Table 23 Pharma by Country.....	330
Table 24 Clinic by Country.....	332
Table 25 Other Customer by Country.....	334
Table 26 2022 Clinical Lab Fee Schedule.....	339
Table 27 The Most Common Assays	431
Table 28 Largest Revenue Assays	436

Table of Figures

Figure 1 Cancer Death Rates – USA, CDC	29
Figure 2 Global healthcare Spending	36
Figure 3 The Lab Test Pie	37
Figure 4 Helper T Cell Roles	49
Figure 5 Antibody Diagram	51
Figure 6 Macrophages attack a Cancer Cell	52
Figure 7 The Tumour Micro Environment.....	65
Figure 8 The Road to Diagnostics.....	68
Figure 9 Comparing IO Diagnostic and Traditional Testing.....	83
Figure 10 Growth rates of IO Diagnostic Technologies.....	86
Figure 11 Global Market Density Chart	286
Figure 12 Global Market by Assay Type - Base vs. Final.....	288
Figure 13 Global Market by Assay Type Base Year	289
Figure 14 Global Market by Assay Type End Year.....	290
Figure 15 Assay Type Share by Year	291
Figure 16 Assay Type Segments Growth.....	292
Figure 17 Global Market by Technology - Base vs. Final	294
Figure 18 Global Market by Technology Base Year.....	295
Figure 19 Global Market by Technology End Year	296
Figure 20 Technology Share by Year	297
Figure 21 Technology Segments Growth	298
Figure 22 Global Market by Customer - Base vs. Final.....	300

Figure 23 Global Market by Customer Base Year	301
Figure 24 Global Market by Customer End Year	302
Figure 25 Customer Share by Year	303
Figure 26 Customer Segments Growth.....	304
Figure 27 Checkpoint Growth	307
Figure 28 Cytokine Growth	309
Figure 29 Germline Genetic Growth	311
Figure 30 Genetic Tumor Growth.....	313
Figure 31 Tumor Microenvironment Growth	315
Figure 32 Other Growth.....	317
Figure 33 NGS Growth	320
Figure 34 PCR Growth	322
Figure 35 Fish/IHC Growth.....	324
Figure 36 Chem/IA Growth.....	326
Figure 37 Other Technology Growth	328
Figure 38 Pharma Growth.....	331
Figure 39 Clinic Growth.....	333
Figure 40 Other Customer Growth.....	335
Figure 41 IVD Test Menu Growth 2011-2022	337
Figure 42 Prevalence of Cancer Treatments.....	338